Search results for "Invasive Mycoses"

showing 2 items of 2 documents

European expert opinion on the management of invasive candidiasis in adults

2011

Item does not contain fulltext This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad ans…

Invasive mycoses and compromised host Translational research [N4i 2]AdultMicrobiology (medical)medicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentPlacebo-controlled studyMEDLINEInvasive mycoses and compromised host Infection and autoimmunity [N4i 2]MicrobiologyMedicineHumanscandidaemiaCandidiasis InvasiveguidelinesIntensive care medicineWatchful Waitingtherapybusiness.industryTreatment optionsPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]General MedicineInvasive candidiasisComparative trialAntibiotic Prophylaxismedicine.diseaseOptimal managementEuropeIntensive Care UnitsInfectious DiseasesconsensusExpert opinioncandidabusinessWatchful waitingClinical Microbiology and Infection
researchProduct

Antifungal prophylaxis for invasive mycoses in high risk patients.

2006

New broader spectrum antifungal agents with favorable safety profiles have been available for the last 15 years making prophylaxis feasible. The purpose of this article is to review recent studies in patient populations at high risk for invasive fungal infections.Itraconazole, lipid formulations of amphotericin B, posaconazole, caspofungin and micafungin have been utilized for prophylaxis in different immunocompromised host settings. Itraconazole and caspofungin remain an option especially in patients with hematological diseases. Low dose liposomal amphotericin B shows a lower morbidity rate in patients treated for acute myeloid leukemia. Posaconazole demonstrated survival benefits in this …

Microbiology (medical)Antifungalmedicine.medical_specialtyClinical Trials as TopicHigh risk patientsAntifungal Agentsbusiness.industrymedicine.drug_classImmunocompromised HostInfectious DiseasesInvasive MycosesMycosesMedicineHumansIn patientbusinessIntensive care medicineCurrent opinion in infectious diseases
researchProduct